An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore - Trial NCT06232265
Access comprehensive clinical trial information for NCT06232265 through Pure Global AI's free database. This phase not specified trial is sponsored by Nanfang Hospital, Southern Medical University and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 108 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Nanfang Hospital, Southern Medical University
Timeline & Enrollment
N/A
Sep 22, 2023
Aug 01, 2026
Primary Outcome
Objective Response Rate (ORR)
Summary
This is a multi-center, observational clinical study to explore the role of LIRAscore in
 predicting immunotherapy monotherapy and combination with chemotherapy efficacy and prognosis
 in locally advanced or metastatic non-small-cell lung cancer. The study plans to enroll 108
 patients. The primary endpoint of this study was ORR, and secondary endpoints were PFS, OS,
 DoR, DCR, and safety.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06232265
Non-Device Trial